Phase 3 trials primed to test sozinibercept for neovascular AMD


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, David A. Eichenbaum, MD, discusses the design of phase 3 trials of sozinibercept for the treatment of neovascular age-related macular degeneration.

Eichenbaum said there have been a number of anti-VEGF-A molecules that have demonstrated improvements in durability, but there have not been as many that have shown improvement in visual acuity. Phase 2 research showed promise for sozinibercept in this area.

“We’re very excited to test sozinibercept in large, phase 3 programs of about 990 patients each with the goal of reproducing those results and showing that we can improve visual acuity, hopefully, by up to five letters or more,” he said.

Source link

error: Content is protected !!